BOTHELL, Wash.--(BUSINESS WIRE)--EKOS Corporation announced today that EKOS and their Netherlands distributor, AngioCare BV, are supporting a Dutch multicentre randomized trial (DUET) designed to ...

BOTHELL, Wash.--(BUSINESS WIRE)--EKOS Corporation announced today the EKOS EkoSonic ® Endovascular System is the first endovascular device approved for the treatment of pulmonary embolism (PE). The ...

Randomized Controlled Multi-Center Trial Demonstrates Reduced Treatment Time and Drug Dose with EKOS vs. Catheter-Directed Thrombolysis in Peripheral Arterial Occlusions EKOS Corporation, a privately ...

In 18 participants, where the EKOS MicroLysus catheter could not access the clot, a standard catheter was used to deliver tPA to the clot site. Partial or complete reopening of the blocked brain ...

London-based health-care company BTG has agreed to buy medical-device maker Ekos of Bothell for $180 million or more, the companies said Friday. Ekos developed an ultrasound-enhanced system for ...

BOTHELL – Ekos Corp., which has spent more than a decade inventing ultrasound-enhanced catheters that can quickly break up blood clots, is ready to sell the device to doctors around the world. The ...

Lurking somewhere, silently, deep in your body may be deep vein thrombosis, a killer blood clot that claims more U.S. lives each year than AIDS and car accidents combined. But new technology at a few ...

A new study using Boston Scientific's EkoSonic endovascular system (EKOS) aims to address current gaps in clinical guidelines for the treatment of pulmonary embolism. The first-of-its-kind trial will ...

BTG Receives U.S. FDA 510(k) Clearance for EKOS® Control Unit 4.0 London, UK, 27 February 2017: BTG plc (LSE: BTG), the global specialist healthcare company, today announced U.S. Food and Drug ...

Standard clot-busting medication combined with low-energy ultrasound appears to reopen clogged arteries in stroke patients better than medication alone, a pilot study led by University of Cincinnati ...